糖尿病是通常与动脉粥样硬化相关的代谢紊乱。具有治疗潜力的植物,如LippiaoriganoidesKunth,成为治疗这些疾病的有效替代品。因此,这项工作旨在分析四氧嘧啶糖尿病大鼠中LippiaoriginanidesKunth(ELo)的水醇提取物的抗高血糖和抗血脂潜能。动物口服治疗:正常对照,高血糖控制,阳性对照格列本脲(5mg/kg),和用ELo治疗的组(75、150和250mg/kg)。ELo的临床前评估显示低血糖,降血脂,肝,和肾脏保护作用。在所有剂量下,ELo显著降低高血糖,甘油三酯,总胆固醇,低密度脂蛋白,致动脉粥样硬化指数,致动脉粥样硬化系数,和心血管风险指数(p<0.05)。与未处理的动物相比,不同剂量的Elo促进胰岛素释放的增加(p<.05),并显示α-葡糖苷酶抑制活性(p<.05)。此外,ELo(250mg/kg组)显示高血糖的最大减少,丙氨酸转氨酶,天冬氨酸转氨酶,丙二醛,和尿素与高血糖组和格列本脲组相比,和肌酐仅与高血糖组相比(p<0.05)。ELo在糖尿病中的有希望的作用可能与液相色谱中鉴定的类黄酮化合物的协同作用有关,其药理能力已经在以前的研究中得到了证明。机制可能是刺激胰岛素释放;α-葡萄糖苷酶的抑制活性;改善一般临床状况;以及提取物的抗氧化作用。这些发现为将来开发具有降脂作用的牛乳杆菌作为降血糖和心血管保护剂的草药形式铺平了道路。
Diabetes mellitus is a metabolic disorder commonly associated with atherosclerosis. Plants with therapeutic potential, such as Lippia origanoides Kunth, emerge as effective alternatives for treating these diseases. Therefore, this work aims to analyze the antihyperglycemic and antidyslipidemic potential of the hydroalcoholic extract of Lippia origanoides Kunth (ELo) in alloxan-diabetic rats. Animals were treated orally: normal control, hyperglycemic control, positive control glibenclamide (5 mg/kg), and groups treated with ELo (75, 150, and 250 mg/kg). Preclinical evaluation of ELo showed
hypoglycemic, hypolipidemic, hepatic, and renal protective effects. At all doses, ELo significantly reduced hyperglycemia, triglycerides, total cholesterol, low-density lipoprotein, atherogenic index, atherogenic coefficient, and cardiovascular risk index (p < .05). Elo at different doses promoted an increase in insulin release compared to untreated animals (p < .05) and showed α-glucosidase inhibitory activity (p < .05). Also, ELo (250 mg/kg group) showed maximum reduction of hyperglycemia, alanine transaminase, aspartate aminotransferase, malonaldehyde, and urea compared to the hyperglycemic and glibenclamide groups, and creatinine only compared to the hyperglycemic groups (p < .05). The promising action of ELo in the context of diabetes may be related to the synergistic action of flavonoid compounds identified in liquid chromatography, whose pharmacological capabilities have already been documented in previous studies. The mechanisms may be the stimulation of insulin release; the inhibitory activity of α-glucosidase; improving general clinical conditions; and the antioxidant effects of the extract. These findings pave the way for the future development of an herbal presentation of L. origanoides Kunth as a
hypoglycemic and cardiovascular protector with a lipid-lowering effect.